Faron Pharmaceuticals Oy Exercise of Options (4134T)
March 25 2021 - 2:45AM
UK Regulatory
TIDMFARN
RNS Number : 4134T
Faron Pharmaceuticals Oy
25 March 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Exercise of options
Issue of equity
Company announcement, 25 March 2020 at 9.45 AM (EET)
TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), the clinical stage biopharmaceutical company,
announces that it has received a notification from Toni Hänninen,
Faron's CFO, to exercise D options over 40,000 ordinary shares in
the Company at an exercise price of EUR 1.09 (approx. GBP 0.94) per
share under the Company's 2015 Option Plan ("New Ordinary Shares").
The terms and conditions of the 2015 Option Plan are available on
the Company's website at
https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf
.
Applications will be made to the London Stock Exchange and
Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM
and Nasdaq First North Growth Market, respectively. Admission of
the New Ordinary Shares is expected to occur on or around 7 April
2021 following issue and registration of the New Ordinary Shares on
or around 6 April 2021 ("Registration"). The New Ordinary Shares
will rank pari passu with existing ordinary shares.
Faron's enlarged issued number of shares immediately following
Registration will be 50,457,874 ordinary shares with voting rights
attached. The Company has no shares in treasury; therefore upon,
and subject to, Registration, the total number of voting rights in
Faron will be 50,457,874. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine whether they are required to notify an interest in, or a
change to their interest in, the issued shares and votes of the
Company.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Broker
Rupert Dearden
Phone: +44 207 886 2500
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel, Naina Zaman
Phone: +1 (212) 362-1200
Email: faron@sternir.com
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanised antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in phase I/II clinical development as a
potential therapy for patients with untreatable solid tumours,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine(R) is an investigational
intravenous (IV) interferon beta-1a therapy for the treatment of
acute respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine(R) is currently being
evaluated in global trials as a potential treatment for
hospitalised patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland. Further information is available at
www.faron.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- ------------------------------------------------------------------------------------
a. Name Toni Hänninen
---------------------------------------------------------
2 Reason for notification
------------------------- ---------------------------------------------------------
a. Position/Status Person discharging managerial responsibilities
------------------------- ---------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
------------------------- ---------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
------------------------- ---------------------------------------------------------
b. LEI 7437009H31TO1DC0EB42
------------------------- ---------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- ------------------------------------------------------------------------------------
a. Description of Options over ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
------------------------- ---------------------------------------------------------
b. Nature of the Exercise of options made pursuant to the Faron
transaction Option Plan 2015 exercisable at EUR1.09 per
ordinary share
------------------------- ---------------------------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
------------------------- ----------
EUR1.09 40,000
---------- ----------
Aggregated information
- Aggregated
Volume 40,000
d. - Price EUR1.09
------------------------- ---------------------------------------------------------
e. Date of the transaction 24 March 2021
------------------------- ---------------------------------------------------------
f. Place of the Turku, Finland
transaction
------------------------- ---------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBZLLLFXLLBBL
(END) Dow Jones Newswires
March 25, 2021 03:45 ET (07:45 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024
